Effect of nebivolol on endothelial nitric oxide and peroxynitrite release in hypertensive animals: Role of antioxidant activity

Journal of Cardiovascular Pharmacology

Volumn 48, Issue 1, 2006, Pages 862-869

  Mason, R Preston ^a,c   Kubant, Ruslan ^b   Jacob, Robert F ^c   Walter, Mary F ^c   Boychuk, Bohdan ^b   Malinski, Tadeusz ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b OHIO UNIVERSITY   (United States)

^c ELUCIDA RESEARCH LLC   (United States)

Author keywords

Endothelium; Nanosensors; Nitric oxide; Nitric oxide synthase; Peroxynitrite

Indexed keywords

ACETYLCHOLINE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIMYCIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; NEBIVOLOL; NITRIC OXIDE; PEROXYNITRITE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE THERAPY; ARTICLE; DRUG EFFECT; HYPERTENSION; LIPID PEROXIDATION; LIPID VESICLE; MEMBRANE STRUCTURE; MESENTERIC ARTERY; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; RAT; RESISTANCE BLOOD VESSEL; SPONTANEOUSLY HYPERTENSIVE RAT; VASCULAR ENDOTHELIUM; X RAY DIFFRACTION;

ACETYLCHOLINE; ANIMALS; ANTIHYPERTENSIVE AGENTS; ANTIOXIDANTS; ATENOLOL; BENZOPYRANS; CALCIMYCIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; ETHANOLAMINES; FEMALE; FOURIER ANALYSIS; HYPERTENSION; LIPID BILAYERS; LIPID PEROXIDATION; MALE; MESENTERIC ARTERIES; NANOTECHNOLOGY; NITRIC OXIDE; PEROXYNITROUS ACID; RATS; RATS, INBRED SHR; RATS, INBRED WKY; SOLUBILITY; STEREOISOMERISM; X-RAY DIFFRACTION;

EID: 33747809601     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000238593.67191.e2     Document Type: Article

References (38)

1. Oemar BS, Tschudi MR, Godoy N, et al. Reduced endothelial nitric oxide synthase expression and production in human atherosclerosis. Circulation. 1998;97:2494-2498.
2. Harrison DG, Freiman PC, Armstrong ML, et al. Alterations of vascular reactivity in atherosclerosis. Circ Res. 1987;61:74-80.
3. Liao JK. Endothelium and acute coronary syndromes. Clin Chem. 1998;44:1799-1808.
4. Paniagua OA, Bryant MB, Panza JA. Role of endothelial nitric oxide in shear stress-induced vasodilatation in human microvasculature. Diminished activity in hypertensive and hypercholesterolemic patients. Circulation. 2001;103:1752-1758.
5. Panza JA, Quyyumi AA, Brush JE, et al. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med. 1990;323:22-27.
6. Taddei S, Virdis A, Mattei P, et al. Vasodilatation to acetylcholine in primary and secondary forms of human hypertension. Hypertension. 1993;21:929-933.
7. Harrison DG. Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest. 1997;100:2153-2157.
8. Campia U, Choucair WK, Bryant MB, et al. Reduced endothelium-dependent and -independent dilation of conductance arteries in African Americans. J Am Coll Cardiol. 2002;40:754-760.
9. Stein CM, Lang CC, Nelson R, et al. Vasodilatation in black Americans: Attenuated nitric oxide-mediated responses. Clin Pharmacol Ther. 1997;62:436-443.
10. Kalinowski L, Dobrucki I, Malinski T. Race-specific differences in endothelial function: Predisposition of African Americans to vascular diseases. Circulation. 2004;109:2511-2517.
11. Xhonneux R, Wouters L, Reneman RS, et al. The l-enantiomer of nebivolol potentiates the blood pressure lowering effect of the d-enantiomer. Eur J Pharmacol. 1990;181:261-265.
12. Bowman AJ, Chen CP, Ford GA. Nitric oxide mediated venodilator effects of nebivolol. Br J Clin Pharmacol. 1994;38:199-204.
13. Broeders MA, Doevendans PA, Bekkers BC, et al. Nebivolol: a third-generation beta-blocker that augments vascular nitric oxide release: endothelial beta(2)-adrenergic receptor-mediated nitric oxide production. Circulation. 2000;102:677-684.
14. Kalinowski L, Dobrucki LW, Szczepanska-Konkel M, et al. Third-generation β-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action. Circulation. 2003;107:2747-2752.
15. Mollnau H, Schulz E, Daiber A, et al. Nebivolol prevents vascular NOS III uncoupling in experimental hyperlipidemia and inhibits NADPH oxidase activity in inflammatory cells. Arterioscler Thromb Vasc Biol. 2003;23:615-621.
16. Troost R, Schwedhelm E, Rojczyk S, et al. Nebivolol decreases systemic oxidative stress in healthy volunteers. Br J Clin Pharmacol. 2000;50:377-379.
17. McIntyre M, Hamilton CA, Rees DD, et al. Sex differences in the abundance of endothelial nitric oxide in a model of genetic hypertension. Hypertension. 1997;30:1517-1524.
18. Kerr S, Brosnan MJ, McIntyre M, et al. Superoxide anion production is increased in a model of genetic hypertension role: of the endothelium. Hypertension. 1999;33:1353-1358.
19. Landmesser U, Cai H, Dikalov S, et al. Role of p47(phox) in vascular oxidative stress and hypertension caused by angiotensin II. Hypertension. 2002;40:511-515.
20. Landmesser U, Dikalov S, Price SR, et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest. 2003;111:1201-1209.
21. El-Saadani M, Esterbauer H, el-Sayed M, et al. A spectrophotometric assay for lipid peroxides in serum lipoproteins using a commercially available reagent. J Lipid Res. 1989;30:627-630.
22. Malinski T, Taha Z. Nitric oxide release from a single cell measured in situ by a porphyrinic-based microsensor. Nature. 1992;358:676-678.
23. Blatter LA, Taha Z, Mesaros S, et al. Simultaneous measurements of Ca2+ and nitric oxide in bradykinin-stimulated vascular endothelial cells. Circ Res. 1995;76:922-924.
24. Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol. 1965;13:238-252.
25. Chester DW, Herbette LG, Mason RP, et al. Diffusion of dihydropyridine calcium channel antagonists in cardiac sarcolemmal lipid multibilayers. Biophys J. 1987;52:1021-1030.
26. Mason RP, Gonye GE, Chester DW, et al. Partitioning and location of Bay K 8644, 1,4-dihydropyridine calcium channel agonist, in model and biological membranes. Biophys J. 1989;55:769-778.
27. Mason RP, Jacob RF. X-ray diffraction analysis of membrane structure changes with oxidative stress. In: Armstrong D, ed. Methods in Molecular Biology: Ultrastructural and Molecular Biology Protocols. Totowa, NJ: Humana Press; 2002:71-80.
28. Tulenko TN, Chen M, Mason PE, et al. Physical effects of cholesterol on arterial smooth muscle membranes: Evidence of immiscible cholesterol domains and alterations in bilayer width during atherogenesis. J Lipid Res. 1998;39:947-956.
29. Herbette LG, MacAlister T, Ashavaid TF, et al. Structure-function studies of canine cardiac sarcolemmal membranes. II. Structural organization of the sarcolemmal membrane as determined by electron microscopy and lamellar x-ray diffraction. Biochim Biophys Acta. 1985;812:609-623.
30. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: Is it a wise choice? Lancet. 2004;364:1684-1689.
31. Bouloumié A, Bauersachs J, Ling W, et al. Endothelial dysfunction coincides with an enhanced nitric oxide synthase expression and superoxide anion production. Hypertension. 1997;30:934-941.
32. Carew TE, Schwenke DC, Steinberg D. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: Evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in theWatanabe heritable hyperlipidemic rabbit. Proc Natl Acad Sci U S A. 1987;84:7725-7729.
33. Parthasarathy S, Young SG, Witztum JL, et al. Probucol inhibits oxidative modification of low density lipoprotein. J Clin Invest. 1986;77:641-644.
34. Janssen PM, Zeitz O, Hasenfuss G. Transient and sustained impacts of hydroxyl radicals on sarcoplasmic reticulum function: Protective effects of nebivolol. Eur J Pharmacol. 1999;366:223-232.
35. de Groot AA, Mathy MM, van Zwieten PA, et al. Antioxidant activity of nebivolol in the rat aorta. J Cardiovasc Pharmacol. 2004;43:148-153.
36. Consentino F, Bonetti S, Rehorik R, et al. Nitric-oxide-mediated relaxations in salt-induced hypertension: Effect of chronic beta1-selective receptor blockade. J Hypertens. 2002;20:421-428.
37. Schiffrin EL, Park JB, Pu Q. Effect of crossing over hypertensive patients from a beta-blocker to an angiotensin receptor antagonist on resistance artery structure and on endothelial function. J Hypertens. 2002;20:71-78.
38. Kamp O, Sieswerda GT, Visser CA. Comparison of effects of systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertension. Am J Cardiol. 2003;92:344-348.